Current Editions
The cytokine sits at the intersection of tumor immune evasion and muscle wasting, offering drug developers a rare chance to address both at once
Product Development
Product Development
ALS clinical trials veteran Genge sees progress in pathway prioritization, progression modeling, endpoint execution and biomarker development
Editor's Commentary
BioCentury is expanding its horizon-scanning tools, data, and analysis to help drug hunters track where translational science is heading next
Discovery & Translation
The city has a dedicated effort to turn its clinical depth, manufacturing and capital into a repeatable path from discovery to medicines
Politics, Policy & Law
Lawsuit refutes government assertions, lists harms beyond Biosecure
Finance
Plus: Follow-ons for Tango and Enliven, and more
Management Tracks
Plus: Ambros taps pair of Regulus vets; the U.K.’s BIA gets a new CEO; and more
BioCentury ISSN 1097-7201